【摘要】 膀胱过度活动症(OAB)是一种常见多发疾病,其治疗主要是保守治疗,抗毒蕈碱药是目前治疗OAB的一线药物。但抗毒蕈碱药对于部分OAB无效,而且该类药物的不良反应限制了其广泛应用。近年来,随着OAB病理机制的深入研究,大量基础和临床研究证实β3-肾上腺素受体(β-3AR)激动剂有望成为治疗OAB的一类新药。本文就β-3AR激动剂的药理特征、有效性、安全性和耐受性进行综述。更多还原

【Abstract】 The overactive bladder syndrome(OAB) is a prevalent condition among adults. Currently, the presenttreatment is mainly conservative therapy. Antimuscarinic drugs are currently the first-line treatment for OAB. However,many patients experienced insufficient therapeutic benefit and/or unpleasant side effects. Recent advances in the understand-ing of the physiopathology of OAB have driven a huge amount of basic and clinical research into novel pharmacological com-pounds. β3-adrenoceptor agonists are an emerging drug class for the treatment of the OAB. This study reviewed the pharma-cological profile of β3-adrenoceptor agonists and discussed the efficacy, safety and tolerability.更多还原